Randomized Controlled Trial on the Effects of Yiqi Fumai Keli on Recurrence in Patients with Atrial Fibrillation after Radiofrequency Ablation

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000003986

Enrollment

Unknown

Registered

2020-09-27

Start date

2020-10-09

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Experimental group:Take Yiqi Fumai Granule for 3 months

control group:Take the granule placebo for 3 months

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The patients met the diagnostic criteria of atrial fibrillation and underwent radiofrequency ablation successfully; (2) TCM syndrome differentiation is in accordance with Qi deficiency and blood stasis, phlegm heat disturbing heart syndrome; (3) Aged 18-80 years old; (4) Volunteer to participate and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Severe structural heart disease, heart failure (LVEF <=40%), serious arrhythmia such as persistent ventricular tachycardia; (2) Thyroid disease, severe liver and kidney disease, mental illness and malignant tumor, pregnant women and breast-feeding; (3) Participants in other clinical trials within 3 months; (4) Patients who used other antiarrhythmic Chinese patent medicines and their preparations.

Design outcomes

Primary

Measure	Time frame
Recurrence rate of atrial fibrillation;	—

Secondary

Measure	Time frame
TCM Syndrome Evaluation;	—

Countries

China

Contacts

Public ContactJiqiang Hu

Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine

hujiqiang0923@163.com+86 13522675198

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026